In the first model, evaluating mice with HER2+ ovarian cancer cells, the CAT-179-dosed animals showed a 95% decline in tumor burden (p < 0.0001) and a significant survival benefit relative to the animals dosed with control NK cells (p < 0.0001). Here, ERBB2 is linked to ovarian carcinoma.